Diaceutics PLC
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. It also provides DXRX data solutions, including DXRX Signal, which d… Read more
Diaceutics PLC (DIUXF) - Total Liabilities
Latest total liabilities as of June 2025: $7.18 Million USD
Based on the latest financial reports, Diaceutics PLC (DIUXF) has total liabilities worth $7.18 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Diaceutics PLC - Total Liabilities Trend (2015–2024)
This chart illustrates how Diaceutics PLC's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Diaceutics PLC Competitors by Total Liabilities
The table below lists competitors of Diaceutics PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Midsona AB (publ)
ST:MSON-A
|
Sweden | Skr1.46 Billion |
|
HKR International Limited
F:HKR
|
Germany | €18.29 Billion |
|
PT Buma Internasional Grup Tbk
JK:DOID
|
Indonesia | Rp1.44 Billion |
|
Yi Jinn Industrial Co Ltd
TW:1457
|
Taiwan | NT$8.48 Billion |
|
Jasuindo Tiga Perkasa Tbk
JK:JTPE
|
Indonesia | Rp768.02 Billion |
|
Westag & Getalit AG
F:WUG3
|
Germany | €47.09 Million |
|
Motonic
KO:009680
|
Korea | ₩46.40 Billion |
|
Asuransi Jiwa Sinarmas Msig PT
JK:LIFE
|
Indonesia | Rp6.71 Trillion |
Liability Composition Analysis (2015–2024)
This chart breaks down Diaceutics PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Diaceutics PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Diaceutics PLC (2015–2024)
The table below shows the annual total liabilities of Diaceutics PLC from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $8.76 Million | +57.66% |
| 2023-12-31 | $5.56 Million | -3.20% |
| 2022-12-31 | $5.74 Million | +31.58% |
| 2021-12-31 | $4.36 Million | +33.01% |
| 2020-12-31 | $3.28 Million | +46.54% |
| 2019-12-31 | $2.24 Million | -56.78% |
| 2018-12-31 | $5.18 Million | +43.37% |
| 2017-12-31 | $3.61 Million | +48.82% |
| 2016-12-31 | $2.43 Million | +106.72% |
| 2015-12-31 | $1.17 Million | -- |